Ligand validation:4XRN

C2E: 9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)

C2E is a Ligand Of Interest in 4XRN designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4XRN_C2E_C_203	80%	2%	0.112	0.961	5.12	1.68	35	12	2	0	100%	1
4XRN_C2E_D_201	78%	2%	0.111	0.955	5.08	1.71	34	14	0	0	100%	1
4XRN_C2E_C_201	78%	2%	0.119	0.962	5.08	1.62	35	15	0	0	100%	1
4XRN_C2E_C_202	75%	2%	0.126	0.96	4.99	1.64	34	15	0	0	100%	1
4XRN_C2E_A_201	73%	2%	0.105	0.931	5.17	1.71	34	15	1	0	100%	1
4XRN_C2E_D_202	70%	2%	0.125	0.941	5.15	1.63	34	12	0	0	100%	1
4XRN_C2E_B_202	69%	2%	0.132	0.946	5.17	1.67	33	14	2	0	100%	1
4XRN_C2E_B_203	67%	2%	0.124	0.932	5.18	1.68	33	13	0	0	100%	1
4XRN_C2E_B_201	66%	2%	0.118	0.922	5.21	1.72	33	13	8	0	100%	1
4XRN_C2E_A_203	65%	2%	0.13	0.931	5.26	1.72	34	14	0	0	100%	1
4XRN_C2E_D_203	61%	2%	0.137	0.925	5.2	1.86	34	15	3	0	100%	1
4XRN_C2E_A_202	55%	2%	0.142	0.91	5.14	1.9	34	20	9	0	100%	1
4RT1_C2E_B_201	99%	17%	0.054	0.982	2.38	1.24	11	7	0	0	100%	1
4RT0_C2E_A_202	98%	13%	0.05	0.974	2.34	1.6	11	13	0	0	100%	1
8U0I_C2E_A_102	100%	40%	0.042	0.984	1.15	1.19	6	6	0	0	100%	1
4URG_C2E_A_1241	97%	16%	0.065	0.983	2.24	1.49	10	10	0	0	100%	1
5HTL_C2E_B_201	97%	17%	0.057	0.973	2.34	1.3	15	8	1	0	100%	1
2RDE_C2E_B_301	97%	45%	0.067	0.983	0.93	1.18	2	6	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.